Technology Review - Published By MIT
Advertisement
TO READ THIS STORY - you must have a paid subscription to Technology Review OR you can purchase special archive reading credits here. Choose from these great offers below.
I'm a paid subscriber please
log me in
I want to purchase this article for
only $1.99
(requires login)
I want to purchase five articles for
only $7.99
(requires login)
I want to buy
1 Year TOTAL Access for
only $24.95
(requires login)

Please note: Click here if you are currently a Technology Review print or digital subscriber and do not have access to this article.

March 2001

An End to Alzheimer's?

Isolation of key genes at the heart of Alzheimer's disease has set off a frenzied race to find a drug to stop this cruel affliction in its tracks.

By Ken Garber

When molecular biologist Bob Vassar joined biotech giant Amgen in 1996, his mother was suffering from advanced-stage Alzheimer's disease. For years he'd taken care of her himself, since his father had died young. "Once she became incontinent I couldn't keep her at home any more," he recalls with more than a trace of guilt. In a nursing home, Vassar's mother slid rapidly downhill. In 1999, at age 78, she died-17 years after her diagnosis of Alzheimer's, which gradually but inexorably drains its victims of memory, judgment and reason.

Select from the choices above
to read the entire article.


Log In

Forgot your password?     Register »
Advertisement

Videos

Microsoft's Many Multitouch Mice
Advertisement
Advertisement
Advertisement
Subscribe to Technology Review's daily e-mail update. Enter your e-mail address

TECHNOLOGY RESOURCES

More Technology News from Forbes

Advertisement
MIT Massachusetts Institute of Technology © 2009 Technology Review. All Rights Reserved.